Palisade Bio Inc. Common Stock (PALI)

About PALI

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn's disease…

Sector

Health Care

Industry

Biotechnology: Biological Products (No Diagnostic Substances)

Employees

14

Website

palisadebio.com/

Fundamentals

1-day range

$1.99$2.11

Market cap

$336.74M

P/E (trailing)

3.25

P/E (forward)

-7.14

EPS (trailing)

$-1.17

Dividend yield

—

Beta

1.52

Avg. volume

2.99M

Dividend pay date

July 18, 2019

Forecasts

9 analyst ratings

Palisade Bio Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• PALI

  Palisade Bio Inc. Common Stock

  $2.01

  ▼ 4.74%
  Market cap $336.74MP/E 3.25
  $0.53$2.86
• FENC

  Fennec Pharmaceuticals Inc. Common Stock

  $12.19

  ▲ 3.57%
  Market cap $334.56MP/E —
  $5.65$13.25
• AGEN

  Agenus Inc. Common Stock

  $7.67

  ▼ 1.79%
  Market cap $349.96MP/E 4.88
  $2.71$8.85
• IPSC

  Century Therapeutics Inc. Common Stock

  $2.03

  ▼ 9.19%
  Market cap $357.10MP/E —
  $0.435$3.04
• NMRA

  Neumora Therapeutics Inc. Common Stock

  $1.38

  ▼ 6.76%
  Market cap $303.87MP/E —
  $0.83015$3.65
• SABS

  SAB Biotherapeutics Inc. Common Stock

  $3.79

  ▼ 3.56%
  Market cap $289.80MP/E 26.94
  $1.85$5.15
• XFOR

  X4 Pharmaceuticals Inc. Common Stock

  $4.05

  ▼ 4.26%
  Market cap $385.77MP/E 2.95
  $2.8$4.83

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Palisade Bio Q2 EPS $(0.05), Inline, Sales $500.000K
  Benzinga · 8/10/2026

• Robert Baltera Jr. · July 9, 2026 · Buy

  25.0K @ $1.96
• Robert Baltera Jr. · July 8, 2026 · Buy

  20.0K @ $1.99
• Robert Baltera Jr. · July 7, 2026 · Buy

  30.0K @ $2.03
• Mitchell Lawrence Jones · July 7, 2026 · Sale

  51.9K @ $2.05
• John David Finley · July 7, 2026 · Option Exercise

  133 @ $0.7
• John David Finley · July 7, 2026 · Sale

  146.8K @ $2.07
• Robert Baltera Jr. · July 6, 2026 · Buy

  20.0K @ $2.05
• Mitchell Lawrence Jones · July 6, 2026 · Option Exercise

  131.2K
• John David Finley · July 6, 2026 · Option Exercise

  335.2K
• Robert Baltera Jr. · July 2, 2026 · Buy

  10.0K @ $1.98
• Robert Baltera Jr. · July 1, 2026 · Buy

  20.0K @ $1.98
• Robert Baltera Jr. · June 10, 2026 · Grant

  336.9K
• Binxian Wei · June 10, 2026 · Option Exercise

  20.2K
• Binxian Wei · June 10, 2026 · Grant

  592.3K
• Donald Allen Williams · June 10, 2026 · Option Exercise

  60.7K

Institutional Ownership

March 31, 2026

Total shares held

145.96M

Total value held

$255.09M

Institutional holders

93